Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Orphanet Journal of Rare Diseases
Published in: Orphanet Journal of Rare Diseases 1/2018

Open Access 01-12-2018 | Review

A review of scoring systems for ocular involvement in chronic cutaneous bullous diseases

Authors: Brendon W. H. Lee, Jeremy C. K. Tan, Melissa Radjenovic, Minas T. Coroneo, Dedee F. Murrell

Published in: Orphanet Journal of Rare Diseases | Issue 1/2018

Login to get access

Abstract

Background

Epidermolysis bullosa (EB) and autoimmune blistering diseases (AIBD) describe a group of rare chronic dermatoses characterized by cutaneous fragility and blistering. Although uncommon, significant ocular surface disease (OSD) may occur in both and require ophthalmological assessment. Disease scoring systems have a critical role in providing objective and accurate assessment of disease severity. The objectives of this report were, firstly, to document the prevalence and severity of ocular involvement in EB/AIBD. Secondly, to review and evaluate existing ocular and systemic scoring systems for EB/AIBD. Finally, to identify areas where further development of ocular specific tools in EB/AIBD could be pursued.

Methods

A literature search was performed in October 2017 utilising Medline, Embase, and Scopus databases. The results were restricted by date of publication, between 01.01.1950 and 31.10.2017. The reference lists of these articles were then reviewed for additional relevant publications. Articles of all languages were included if an English translation was available. Articles were excluded if they were duplicates, had no reference to ocular involvement in EB/AIBD or described ocular involvement in other diseases.

Results

Descriptions of ocular involvement in EB/AIBD were identified in 88 peer-reviewed journal articles. Findings reported include but are not limited to: cicatrising conjunctivitis, meibomian gland dysfunction, dry eye disease, trichiasis, symblepharon, fornix fibrosis, keratopathy, ectropion/entropion, ankyloblepharon, corneal ulceration, visual impairment and blindness. Although scoring systems exist for assessment of OSD in mucous membrane pemphigoid, no such tools exist for the other AIBD subtypes or for EB. Several systemic scoring systems exist in the dermatological literature that are efficacious in grading overall EB/AIBD severity, but have limited inclusion of ocular features. To the best of our knowledge, there is no recognised or validated scoring systems which comprehensively stages or grades the spectrum of ocular manifestations in EB/AIBD.

Conclusions

There are a range of ocular complications documented in EB and AIBD. Development of a comprehensive ocular scoring system for EB/AIBD which incorporates the delineation between ‘activity’ and ‘damage’ would facilitate more objective patient assessment, improved longitudinal monitoring, comparison of intervention outcomes, and provide commonality for discussion of these patients due to the multidisciplinary nature of their care.
Literature
1.
Horner ME, Abramson AK, Warren RB, Swanson S, Menter MA. The spectrum of oculocutaneous disease: part I. Infectious, inflammatory, and genetic causes of oculocutaneous disease. J Am Acad Dermatol 2014;70. 795:e791–25.
2.
Baum S, Sakka N, Artsi O, Trau H, Barzilai A. Diagnosis and classification of autoimmune blistering diseases. Autoimmun Rev. 2014;13:482–9.PubMedCrossRef
3.
Figueira EC, Murrell DF, Coroneo MT. Ophthalmic involvement in inherited epidermolysis bullosa. Dermatol Clin. 2010;28:143–52.PubMedCrossRef
4.
Destro M, Wallow IL, Brightbill FS. Recessive dystrophic epidermolysis bullosa. Arch Ophthalmol. 1987;105:1248–52.PubMedCrossRef
5.
Tan JCK, Tat LT, Francis KB, Mendoza CG, Murrell DF, Coroneo MT. Prospective study of ocular manifestations of pemphigus and bullous pemphigoid identifies a high prevalence of dry eye syndrome. Cornea. 2015;34:443–8.PubMedCrossRef
6.
Fine JD, Mellerio JE. Extracutaneous manifestations and complications of inherited epidermolysis bullosa: part I. Epithelial associated tissues. J Am Acad Dermatol. 2009;61:367–84. quiz 385-366PubMedCrossRef
7.
Broussard KC, Leung TG, Moradi A, Thorne JE, Fine J-D. Autoimmune bullous diseases with skin and eye involvement: cicatricial pemphigoid, pemphigus vulgaris, and pemphigus paraneoplastica. Clin Dermatol. 2016;34:205–13.PubMedCrossRef
8.
Tan JCK, Murrell DF, Coroneo MT. Ocular involvement in autoimmune blistering skin diseases. In: Murrell DF, editor. Blistering diseases: clinical features, pathogenesis, treatment. Berlin, Heidelberg: Springer; 2015. p. 449–55.
9.
Fine JD, Bruckner-Tuderman L, Eady RAJ, Bauer EA, Bauer JW, Has C, et al. Inherited epidermolysis bullosa: updated recommendations on diagnosis and classification. J Am Acad Dermatol. 2014;70:1103–26.PubMedCrossRef
10.
Pernet G. Involvement of the eyes in a case of epidermolysis bullosa. Ophthalmoscope. 1904;2:308–9.
11.
Cohen M, Sulzberger MB. Essential shrinkage of the conjunctiva in a case of probable epidermolysis bullosa dystrophica. Trans Am Ophthalmol Soc. 1934;32:50–63.PubMedPubMedCentral
12.
Sorsby A, Roberts JAF, Brain RT. Essential shrinking of the conjunctiva in a hereditary affection allied to epidermolysis bullosa. Doc Ophthalmol. 1951;5-6:118–50.PubMedCrossRef
13.
Aurora AL, Madhavan M, Rao S. Ocular changes in epidermolysis bullosa letalis. Am J Ophthalmol. 1975;79:464–70.PubMedCrossRef
14.
Hammerton ME, Turner TW, Pyne RJ. A case of junctional epidermolysis bullosa (Herlitz-Pearson) with corneal bullae. Aust J Ophthalmol. 1984;12:45–8.PubMedCrossRef
15.
Lechner S, Pleyer U, Hartmann C. Conjunctival mixed injection with membrane development. Ocular involvement in epidermolysis bullosa hereditaria generalisata atrophicans. Ophthalmologe. 2002;99:960–1.PubMedCrossRef
16.
17.
Irak I, Soll SM, Camacho JM. Junctional epidermolysis bullosa in a young patient. J Pediatr Ophthalmol Strabismus. 2003;40:168–9.PubMed
18.
19.
Granek H, Baden HP. Corneal involvement in epidermolysis bullosa simplex. Arch Ophthalmol. 1980;98:469–72.PubMedCrossRef
20.
Steuhl KP, Anton-Lamprecht I, Arnold ML, Thiel HJ. Recurrent bilateral corneal erosions due to an association of epidermolysis bullosa simplex Köbner and X-linked ichthyosis with steroid sulfatase deficiency. Graefes Arch Clin Exp Ophthalmol. 1988;226:216–23.PubMedCrossRef
21.
22.
McDonnell PJ, Schofield OM, Spalton DJ, Eady RA. Eye involvement in junctional epidermolysis bullosa. Arch Ophthalmol. 1989;107:1635–7.PubMedCrossRef
23.
Gans LA. Eye lesions of epidermolysis bullosa. Clinical features, management, and prognosis. Arch Dermatol. 1988;124:762–4.PubMedCrossRef
24.
Lin AN, Murphy F, Brodie SE, Carter DM. Review of ophthalmic findings in 204 patients with epidermolysis bullosa. Am J Ophthalmol. 1994;118:384–90.PubMedCrossRef
25.
26.
Silverberg M, Fan-Paul N, Kane S, Medow N. Junctional epidermolysis bullosa in the neonate: a case report. J Pediatr Ophthalmol Strabismus. 1999;36:219–20.PubMed
27.
Fine JD, Johnson LB, Weiner M, Stein A, Cash S, Deleoz J, et al. Eye involvement in inherited epidermolysis bullosa: experience of the National Epidermolysis Bullosa Registry. Am J Ophthalmol. 2004;138:254–62.PubMedCrossRef
28.
Gedde-Dahl TJ. Epidermolysis bullosa: a clinical, genetic and epidemiological study. 1st ed. Baltimore: Johns Hopkins University Press; 1971.
29.
Breit R. Epidermolysis bullosa dystrophica inversa, a review and case report. Hautarzt. 1979;30:471–7.PubMed
30.
Jen M, Nallasamy S. Ocular manifestations of genetic skin disorders. Clin Dermatol. 2016;34:242–75.PubMedCrossRef
31.
El Hachem M, Diociaiuti A, Proto V, Fortugno P, Zambruno G, Castiglia D, et al. Kindler syndrome with severe mucosal involvement in a large Palestinian pedigree. Eur J Dermatol. 2015;25:14–9.PubMed
32.
Stoiber J. Ophthalmological aspects of epidermolysis bullosa. In: Fine JD, Hintner H, editors. Life with epidermolysis bullosa (EB): etiology, diagnosis, multidisciplinary care and therapy. Austria: springer; 2009. p. 132–43.
33.
Fine JD, Eady RAJ, Bauer EA, Bauer JW, Bruckner-Tuderman L, Heagerty A, et al. The classification of inherited epidermolysis bullosa (EB): report of the third international consensus meeting on diagnosis and classification of EB. J Am Acad Dermatol. 2008;58:931–50.PubMedCrossRef
34.
Fine JD, Johnson LB, Suchindran CM. The National Epidermolysis Bullosa Registry. J Invest Dermatol. 1994;102:54S–6S.PubMedCrossRef
35.
Smith KAV, Jones SM, Nischal KK. Refractive and ocular motility findings in children with epidermolysis bullosa. Am Orthopt J. 2009;59:76–83.PubMedCrossRef
36.
Matsumoto Y, Dogru M, Tsubota K. Ocular surface findings in Hallopeau-Siemens subtype of dystrophic epidermolysis bullosa: report of a case and literature review. Cornea. 2005;24:474–9.PubMedCrossRef
37.
Bron AJ, Benjamin L, Snibson GR. Meibomian gland disease. Classification and grading of lid changes. Eye (Lond). 1991;5:395–411.PubMedCrossRef
38.
Jones SM, Smith KA, Jain M, Mellerio JE, Martinez A, Nischal KK. The frequency of signs of meibomian gland dysfunction in children with epidermolysis bullosa. Ophthalmology. 2016;123:991–9.PubMedCrossRef
39.
Adamis AP, Schein OD, Kenyon KR. Anterior corneal disease of epidermolysis bullosa simplex. Arch Ophthalmol. 1993;111:499–502.PubMedCrossRef
40.
Laforest C, Huilgol SC, Casson R, Selva D, Leibovitch I. Autoimmune bullous diseases: ocular manifestations and management. Drugs. 2005;65:1767–79.PubMedCrossRef
41.
Kirzhner M, Jakobiec FA. Ocular cicatricial pemphigoid: a review of clinical features, immunopathology, differential diagnosis, and current management. Semin Ophthalmol. 2011;26:270–7.PubMedCrossRef
42.
Leonard JN, Hobday CM, Haffenden GP, Griffiths CE, Powles AV, Wright P, et al. Immunofluorescent studies in ocular cicatricial pemphigoid. Br J Dermatol. 1988;118:209–17.PubMedCrossRef
43.
44.
Dart JK. The 2016 Bowman lecture conjunctival curses: scarring conjunctivitis 30 years on. Eye (Lond). 2017;31:301–32.CrossRef
45.
Chan LS, Ahmed AR, Anhalt GJ, Bernauer W, Cooper KD, Elder MJ. The first international consensus on mucous membrane pemphigoid: definition, diagnostic criteria, pathogenic factors, medical treatment, and prognostic indicators. Arch Dermatol. 2002;138:370–9.PubMed
46.
Chan LS. Ocular and oral mucous membrane pemphigoid (cicatricial pemphigoid). Clin Dermatol. 2012;30:34–7.PubMedCrossRef
47.
Saw VP, Dart JK, Rauz S, Ramsay A, Bunce C, Xing W. Immunosuppressive therapy for ocular mucous membrane pemphigoid strategies and outcomes. Ophthalmology. 2008;115:253–61.PubMedCrossRef
48.
49.
Foster CS, Wilson LA, Ekins MB. Immunosuppressive therapy for progressive ocular cicatricial pemphigoid. Ophthalmology. 1982;89:340–53.PubMedCrossRef
50.
Venning VA, Frith PA, Bron AJ, Millard PR, Wojnarowska F. Mucosal involvement in bullous and cicatricial pemphigoid. A clinical and immunopathological study. Br J Dermatol. 1988;118:7–15.PubMedCrossRef
51.
Hardy KM, Perry HO, Pingree GC, Kirby TJ Jr. Benign mucous membrane pemphigoid. Arch Dermatol. 1971;104:467–75.PubMedCrossRef
52.
Thorne JE, Anhalt GJ, Jabs DA. Mucous membrane pemphigoid and pseudopemphigoid. Ophthalmology. 2004;111:45–52.PubMedCrossRef
53.
54.
Rauz S, Maddison PG, Dart JK. Evaluation of mucous membrane pemphigoid with ocular involvement in young patients. Ophthalmology. 2005;112:1268–74.PubMedCrossRef
55.
56.
57.
Camisa C, Meisler DM. Immunobullous diseases with ocular involvement. Dermatol Clin. 1992;10:555–70.PubMedCrossRef
58.
Leonard JN, Wright P, Williams DM, Gilkes JJH, Haffenden GP, McMinn RMH, et al. The relationship between linear IgA disease and benign mucous membrane pemphigoid. Br J Dermatol. 1984;110:307–14.PubMedCrossRef
59.
Weller RB, Hunter HJA, Mann MW. Bullous diseases. In: Weller RB, Hunter HJA, Mann MW, editors. Clinical Dermatology. Hoboken, United States: John Wiley & Sons Ltd; 2014. p. 113–125.
60.
Akhyani M, Keshtkar-Jafari A, Chams-Davatchi C, Lajevardi V, Beigi S, Aghazadeh N, et al. Ocular involvement in pemphigus vulgaris. J Dermatol. 2014;41:618–21.PubMedCrossRef
61.
Espana A, Iranzo P, Herrero-Gonzalez J, Mascaro JMJ, Suarez R. Ocular involvement in pemphigus vulgaris - a retrospective study of a large Spanish cohort. J Dtsch Dermatol Ges. 2017;15:396–403.PubMed
62.
Smith RJ, Manche EE, Mondino BJ. Ocular cicatricial pemphigoid and ocular manifestations of pemphigus vulgaris. Int Ophthalmol Clin. 1997;37:63–75.PubMedCrossRef
63.
Fiore JM, Perry HD, Donnenfeld ED, Berger SA. Pemphigus vulgaris: bilateral plica semilunaris involvement. Cornea. 2011;30:357–9.PubMedCrossRef
64.
Chirinos-Saldana P, Zuniga-Gonzalez I, Hernandez-Camarena JC, Navas A, Ramirez-Luquin T, Robles-Contreras A. Cicatricial changes in ocular pemphigus. Eye (Lond). 2014;28:459–65.PubMedPubMedCentralCrossRef
65.
Daoud YJ, Cervantes R, Foster CS, Ahmed AR. Ocular pemphigus. J Am Acad Dermatol. 2005;53:585–90.PubMedCrossRef
66.
Daoud YJ, Foster CS, Razzaque Ahmed A. Eyelid skin involvement in pemphigus foliaceus. Ocul Immunol Inflamm. 2009;13:389–94.CrossRef
67.
Choe CH, Blepharospasm GRE. Apraxia of eyelid opening associated with anti-Hu paraneoplastic antibodies: a case report. Ophthalmology. 2012;119:865–8.PubMedCrossRef
68.
Ahuero AE, Jakobiec FA, Bhat P, Ciralsky JB, Papaliodis GN. Paraneoplastic conjunctival cicatrization: two different pathogenic types. Ophthalmology. 2010;117:659–64.PubMedCrossRef
69.
Beele H, Claerhout I, Kestelyn P, Dierckxens L, Naeyaert JM, De Laey JJ. Bilateral corneal melting in a patient with paraneoplastic pemphigus. Dermatology. 2001;202:147–50.PubMedCrossRef
70.
Tam PM, Cheng LL, Young AL, Lam PT. Paraneoplastic pemphigus: an uncommon cause of chronic cicatrising conjunctivitis. BMJ Case Rep. 2009;2009
71.
Aultbrinker EA, Starr MB, Donnenfeld ED. Linear IgA disease. The ocular manifestations. Ophthalmology. 1988;95:340–3.PubMedCrossRef
72.
Kelly SE, Frith PA, Millard PR, Wojnarowska F, Black MM. A clinicopathological study of mucosal involvement in linear IgA disease. Br J Dermatol. 1988;119:161–70.PubMedCrossRef
73.
Leonard JN, Wright P, Haffenden GP, Williams DM, Griffiths CE, Fry L. Skin diseases and the dry eye. Trans Ophthalmol Soc UK. 1985;104(Pt 4):467–76.PubMed
74.
Elchahal S, Kavosh ER, Chu DS. Ocular manifestations of blistering diseases. Immunol Allergy Clin N Am. 2008;28:119–36. viiCrossRef
75.
Talhari C, Althaus C, Megahed M. Ocular linear IgA disease resulting in blindness. Arch Dermatol. 2006;142:786–7.PubMedCrossRef
76.
Letko E, Bhol K, Foster CS, Ahmed AR. Linear IgA bullous disease limited to the eye: a diagnostic dilemma: response to intravenous immunoglobulin therapy. Ophthalmology. 2000;107:1524–8.PubMedCrossRef
77.
Lang PG Jr, Tapert MJ. Severe ocular involvement in a patient with epidermolysis bullosa acquisita. J Am Acad Dermatol. 1987;16:439–43.PubMedCrossRef
78.
Bauer JW, Schaeppi H, Metze D, Muss W, Pohla-Gubo G, Hametner R, et al. Ocular involvement in IgA-epidermolysis bullosa acquisita. Br J Dermatol. 1999;141:887–92.PubMedCrossRef
79.
Richter BJ, McNutt NS. The spectrum of epidermolysis bullosa acquista. Arch Dermatol. 1979;115:1325–8.PubMedCrossRef
80.
Zierhut M, Thiel HJ, Weidle EG, Steuhl KP, Sonnichsen K, Schaumburg-Lever G. Ocular involvement in epidermolysis bullosa acquisita. Arch Ophthalmol. 1989;107:398–401.PubMedCrossRef
81.
Roenigk HHJ, Ryan JG, Bergfeld WF. Epidermolysis bullosa acquista. Report of three cases and review of all published cases. Arch Dermatol. 1971;103(1):10.CrossRef
82.
Zambruno G, Manca V, Kanitakis J, Cozzani E, Nicolas JF, Giannetti A. Linear IgA bullous dermatosis with autoantibodies to a 290 kd antigen of anchoring fibrils. J Am Acad Dermatol. 1994;31:884–8.PubMedCrossRef
83.
Hashimoto T, Ishiko A, Shimizu H, Tanaka T, Dodd HJ, Bhogal BS, et al. A case of linear IgA bullous dermatosis with IgA anti-type VII collagen autoantibodies. Br J Dermatol. 1996;134:336–9.PubMedCrossRef
84.
Caux F, Kirtschig G, Lemarchand-Venencie F, Venencie PY, Hoang-Xuan T, Robin H, et al. IgA-epidermolysis bullosa acquisita in a child resulting in blindness. Br J Dermatol. 1997;137:270–5.PubMedCrossRef
85.
Dantas PE, Nishiwaki-Dantas MC, Seguim MH, Cursino JW. Bilateral corneal involvement in epidermolysis bullosa acquisita. Cornea. 2001;20:664–7.PubMedCrossRef
86.
Ekong AS, Foster CS, Roque MR. Eye involvement in autoimmune blistering diseases. Clin Dermatol. 2001;19:742–9.PubMedCrossRef
87.
Kiyokawa C, Fujito S, Mori O, Mochizuki M, Hashimoto T. Bullous pemphigoid showing unusual ocular changes. Br J Dermatol. 1998;139:693–6.PubMedCrossRef
88.
Tamai K, Hashimoto I, Hanada K, Ikeda S, Imamura S, Ogawa H. Japanese guidelines for diagnosis and treatment of junctional and dystrophic epidermolysis bullosa. Arch Dermatol Res. 2003;295(Suppl 1):24–8.CrossRef
89.
Moss C, Wong A, Davies P. The Birmingham epidermolysis bullosa severity score: development and validation. Br J Dermatol. 2009;160:1057–65.PubMedCrossRef
90.
Schwieger-Briel A, Chakkittakandiyil A, Lara-Corrales I, Aujla N, Lane AT, Lucky AW, et al. Instrument for scoring clinical outcome of research for epidermolysis bullosa: a consensus-generated clinical research tool. Pediatr Dermatol. 2015;32:41–52.PubMedCrossRef
91.
Loh CCH, Kim J, Su JC, Daniel BS, Venugopal SS, Rhodes LM, et al. Development, reliability, and validity of a novel epidermolysis bullosa disease activity and scarring index (EBDASI). J Am Acad Dermatol. 2014;70:89–97.PubMedCrossRef
92.
93.
94.
Tauber J, Jabbur N, Foster CS. Improved detection of disease progression in ocular cicatricial pemphigoid. Cornea. 1992;11:446–51.PubMedCrossRef
95.
Kawakita T, Kawashima M, Murat D, Tsubota K, Shimazaki J. Measurement of fornix depth and area: a novel method of determining the severity of fornix shortening. Eye (Lond). 2008;23:1115–9.PubMedCrossRef
96.
Williams GP, Saw VPJ, Saeed T, Evans ST, Cottrell P, Curnow SJ, et al. Validation of a fornix depth measurer: a putative tool for the assessment of progressive cicatrising conjunctivitis. Br J Ophthalmol. 2011;95:842–7.PubMedCrossRef
97.
Jutley G, Carpenter D, Hau S, Booth D, Jasim HA, Tay E, et al. Upper and lower conjunctival fornix depth in healthy white caucasian eyes: a method of objective assessment. Eye (Lond). 2016;30:1351–8.PubMedPubMedCentralCrossRef
98.
Khan IJ, Ghauri AJ, Hodson J, Edmunds MR, Cottrell P, Evans S, et al. Defining the limits of normal conjunctival fornix anatomy in a healthy south Asian population. Ophthalmology. 2014;121:492–7.PubMedCrossRef
99.
Reeves GM, Lloyd M, Rajlawat BP, Barker GL, Field EA, Kaye SB. Ocular and oral grading of mucous membrane pemphigoid. Graefes Arch Clin Exp Ophthalmol. 2012;250:611–8.PubMedCrossRef
100.
Rowsey J, Macias-Rodriguez Y, Cukrowski C. A new method for measuring progression in patients with ocular cicatricial pemphigoid. Arch Ophthalmol. 2004;122:179–84.PubMedCrossRef
101.
Francis IC, McCluskey PJ, Walls RS, Wakefield D, Brewer JM. Ocular cicatricial pemphigoid. Aust N Z J Ophthalmol. 1990;18:143–50.PubMedCrossRef
102.
Francis IC, Kappagoda MB, Walls RS, McCluskey PJ, Wakefield D. Conjunctival scarring after eyelid surgery as first sign of ocular cicatricial pemphigoid. Ophthal Plast Reconstr Surg. 1997;13:73–4.PubMedCrossRef
103.
Francis IC, McCluskey PJ, Wakefield D, Branley MG. Medial canthal keratinisation (MCK): a diagnostic sign of ocular cicatricial pemphigoid. Aust N Z J Ophthalmol. 1992;20:350–1.PubMedCrossRef
104.
Munyangango EM, Le Roux-Villet C, Doan S, Pascal F, Soued I, Alexandre M, et al. Oral cyclophosphamide without corticosteroids to treat mucous membrane pemphigoid. Br J Dermatol. 2013;168:381–90.PubMedCrossRef
105.
Murrell DF, Marinovic B, Caux F, Prost C, Ahmed R, Wozniak K, et al. Definitions and outcome measures for mucous membrane pemphigoid: recommendations of an international panel of experts. J Am Acad Dermatol. 2015;72:168–74.PubMedCrossRef
106.
Tepelus TC, Huang J, Sadda SR, Lee OL. Characterization of corneal involvement in eyes with mucous membrane pemphigoid by in vivo confocal microscopy. Cornea. 2017;36:933–41.PubMedCrossRef
107.
Alhatem A, Cavalcanti B, Hamrah P. In vivo confocal microscopy in dry eye disease and related conditions. Semin Ophthalmol. 2012;27:143–53.CrossRef
108.
Villani E, Baudouin C, Efron N, Hamrah P, Kojima T, Patel SV, et al. In vivo confocal microscopy of the ocular surface: from bench to bedside. Curr Eye Res. 2014;39:213–31.PubMedCrossRef
109.
Long Q, Zuo YG, Yang X, Gao TT, Liu J, Li Y. Clinical features and in vivo confocal microscopy assessment in 12 patients with ocular cicatricial pemphigoid. Int J Ophthalmol. 2016;9:730–7.PubMedPubMedCentral
110.
Hecht E, Pitz S, Renieri G. In vivo confocal microscopy for the diagnosis of mucous membrane pemphigoid. Klin Monatsbl Augenheilkd. 2015;232:1077–81.PubMedCrossRef
111.
Barabino S, Rolando M. In vivo confocal microscopy of ocular cicatricial pemphigoid. Ophthalmic Surg Lasers Imaging. 2006;37:175–6.PubMed
112.
Pfutze M, Niedermeier A, Hertl M, Eming R. Introducing a novel autoimmune bullous skin disorder intensity score (ABSIS) in pemphigus. Eur J Dermatol. 2007;17:4–11.PubMed
113.
114.
Murrell DF, Dick S, Ahmed AR, Amagia M, Barnadas MA, Borradori L, et al. Consensus statement on definitions of disease, end points, and therapeutic response for pemphigus. J Am Acad Dermatol. 2008;58:1043–6.PubMedPubMedCentralCrossRef
115.
Murrell DF, Daniel BS, Joly P, Borradori L, Amagai M, Hashimoto T, et al. Definitions and outcome measures for bullous pemphigoid: recommendations by an international panel of experts. J Am Acad Dermatol. 2012;66:479–85.PubMedCrossRef
116.
Schiffman RM, Christianson M, Jacobsen G, Hirsch JD, Reis BL. Reliability and validity of the ocular surface disease index. Arch Ophthamol. 2000;118:615–21.CrossRef
117.
Sotozono C, Ang LPK, Koizumi N, Higashihara H, Ueta M, Inatomi T, et al. New grading system for the evaluation of chronic ocular manifestations in patients with Stevens–Johnson syndrome. Ophthalmology. 2007;114:1294–302.PubMedCrossRef
118.
Gulati A, Sullivan R, Buring JE, Sullivan DA, Dana R, Schaumberg DA. Validation and repeatability of a short questionnaire for dry eye syndrome. Am J Ophthalmol 2006;142. 125-131:e122.
119.
Lemp MA, Baudouin C, Baum J, Dogru M, Foulks GN, Kinoshita S, et al. The definition and classification of dry eye disease: report of the definition and classification Subcommittee of the International dry eye Workshop. Ocul Surf. 2007;5:75–92.CrossRef
120.
Gregory DG. New grading system and treatment guidelines for the acute ocular manifestations of Stevens-Johnson syndrome. Ophthalmology. 2016;123:1653–8.PubMedCrossRef
121.
Mathewson PA, Williams GP, Watson SL, Hodson J, Bron AJ, Rauz S, et al. Defining ocular surface disease activity and damage indices by an international Delphi consultation. Ocul Surf. 2017;15:97–111.PubMedCrossRef
122.
Bowman SJ, Pillemer S, Jonsson R, Asmussen K, Vitali C, Manthorpe R, et al. Revisiting Sjögren's syndrome in the new millennium: perspectives on assessment and outcome measures. Report of a workshop held on 23 march 2000 at Oxford, UK. Rheumatology (Oxford). 2001;40:1180–8.CrossRef
Metadata
Title
A review of scoring systems for ocular involvement in chronic cutaneous bullous diseases
Authors
Brendon W. H. Lee
Jeremy C. K. Tan
Melissa Radjenovic
Minas T. Coroneo
Dedee F. Murrell
Publication date
01-12-2018
Publisher
BioMed Central
Published in
Orphanet Journal of Rare Diseases / Issue 1/2018
Electronic ISSN: 1750-1172
DOI
https://doi.org/10.1186/s13023-018-0823-5

Other articles of this Issue 1/2018

Orphanet Journal of Rare Diseases 1/2018 Go to the issue

Review

Consensus guidelines for newborn screening, diagnosis and treatment of infantile Krabbe disease

Research

Mapping health care of rare diseases: the example of epidermolysis bullosa in Germany

Research

Hypermanganesemia due to mutations in SLC39A14: further insights into Mn deposition in the central nervous system

Research

A continuous repetitive task to detect fatigability in spinal muscular atrophy

Position statement

A perspective on “cure” for Rett syndrome

Research

Latitudinal differences on the global epidemiology of infantile spasms: systematic review and meta-analysis